Interactions of antitumor metallodrugs with serum proteins: advances in characterization using modern analytical methodology.
about
Noble metals in oncologySystems biology of cisplatin resistance: past, present and futureESI mass spectrometry and X-ray diffraction studies of adducts between anticancer platinum drugs and hen egg white lysozymeHuman carbonic anhydrase II as a host for piano-stool complexes bearing a sulfonamide anchorMapping the protein-binding sites for iridium(iii)-based CO-releasing moleculesHydrogen bonding and anticancer properties of water-soluble chiral p-cymene Ru(II) compounds with amino-oxime ligandsSynthesis and anticancer activity of carbosilane metallodendrimers based on arene ruthenium(ii) complexesIn vitro and in vivo evaluation of water-soluble iminophosphorane ruthenium(II) compounds. A potential chemotherapeutic agent for triple negative breast cancerStudy of Interactions between Metallothionein and Cisplatin by using Differential Pulse Voltammetry Brdickás reaction and Quartz Crystal MicrobalanceCytotoxic hydrophilic iminophosphorane coordination compounds of d⁸ metals. Studies of their interactions with DNA and HSA.Transferring the concept of multinuclearity to ruthenium complexes for improvement of anticancer activity.Determination of the binding sites for oxaliplatin on insulin using mass spectrometry-based approaches.Arene-Ru(II)-chloroquine complexes interact with DNA, induce apoptosis on human lymphoid cell lines and display low toxicity to normal mammalian cells.Interaction of a ruthenium hexacationic prism with amino acids and biological ligands: ESI mass spectrometry and NMR characterisation of the reaction products.Combining aspects of the platinum anticancer drugs picoplatin and BBR3464 to synthesize a new family of sterically hindered dinuclear complexes; their synthesis, binding kinetics and cytotoxicity.Reactivity of anticancer metallodrugs with serum proteins: new insights from size exclusion chromatography-ICP-MS and ESI-MSNew ruthenium(II) arene complexes of anthracenyl-appended diazacycloalkanes: effect of ligand intercalation and hydrophobicity on DNA and protein binding and cleavage and cytotoxicity.Mixed ligand μ-phenoxo-bridged dinuclear copper(II) complexes with diimine co-ligands: efficient chemical nuclease and protease activities and cytotoxicity.Pharmacological and molecular effects of platinum(II) complexes involving 7-azaindole derivatives.Platinum anticancer agents and antidepressants: desipramine enhances platinum-based cytotoxicity in human colon cancer cellsEffects of noncovalent platinum drug-protein interactions on drug efficacy: use of fluorescent conjugates as probes for drug metabolism.Cyclometalated Iminophosphorane Gold(III) and Platinum(II) Complexes. A Highly Permeable Cationic Platinum(II) Compound with Promising Anticancer PropertiesOn the discovery, biological effects, and use of Cisplatin and metallocenes in anticancer chemotherapyOrganometallic Palladium Complexes with a Water-Soluble Iminophosphorane Ligand as Potential Anticancer Agents.Mesenchymal stem cells maintain their defining stem cell characteristics after treatment with cisplatin.Resistance to DNA-damaging treatment in non-small cell lung cancer tumor-initiating cells involves reduced DNA-PK/ATM activation and diminished cell cycle arrestNew trends for metal complexes with anticancer activityPreliminary anti-cancer photodynamic therapeutic in vitro studies with mixed-metal binuclear ruthenium(II)-vanadium(IV) complexes.Luminescent iminophosphorane gold, palladium and platinum complexes as potential anticancer agents.Hypoxia-selective inhibition of angiogenesis development by NAMI-A analogues.Potential anticancer heterometallic Fe-Au and Fe-Pd agents: initial mechanistic insights.Analysis of the plasma metalloproteome by SEC-ICP-AES: bridging proteomics and metabolomics.Analytical methodologies for metallomics studies of antitumor Pt-containing drugs.Anticancer activity of metal complexes: involvement of redox processes.Tuning heavy metal compounds for anti-tumor activity: is diversity the key to ruthenium's success?Capillary electrophoretic methods in the development of metal-based therapeutics and diagnostics: new methodology and applications.Organometallic compounds: an opportunity for chemical biology?Anticancer metallodrug research analytically painting the "omics" picture--current developments and future trends.Application of mass spectrometric techniques to delineate the modes-of-action of anticancer metallodrugs.Multi-platinum anti-cancer agents. Substitution-inert compounds for tumor selectivity and new targets.
P2860
Q26777745-682ACE7E-2321-4B17-BD93-41469390EFC5Q26863585-16F4460A-D65B-456E-964F-42915D9616B5Q27643373-104C7A28-AB47-4ED6-B14F-4607B2F98980Q27670566-B4FB208D-C3A3-4946-B1FE-D7C49F87C913Q27719016-2EE28B83-230B-463D-ADAC-7E7C8B659FBFQ28834484-0A854EA5-9F54-4EC6-BC60-8D6EEF1958E5Q30358389-4AE3B80D-9314-44DF-A2D6-2A7DE48351BBQ30398565-A5838497-B8BD-426E-B287-A4094FC35BA1Q30467770-AB413C5C-352A-4C0A-B0C1-EEC4380F1090Q30573290-C36231D8-EB4D-43D5-9BF1-4B18C9B1E1E0Q33640724-B6B5CC52-7F46-493D-92D6-3A2A02C99C47Q33965008-CD7E9FA9-E975-4854-8643-D836335D226BQ34020456-9C03F882-0F21-4F0C-8B05-4BD8C879CC7FQ34327703-F814007D-0D4F-4AFF-8BF4-61313C7B9022Q34377003-76DCCCA5-68B4-432A-B130-D8548D9D155AQ34394993-7B177CE8-6280-45F1-B2C6-C34543772D8EQ35029887-4AE69926-D28D-44E6-AF13-097898811FDDQ35111438-A96F8B4D-6172-4A51-9D59-F19EF0BE0B1FQ35112827-7E22D58D-8E20-43A2-848E-31C191204F79Q35647227-82A7897B-ED13-45DF-A02B-D3CB6DD04158Q35925653-AABF90BF-7880-4376-A988-6841424799F6Q35961028-D9ADDED9-A81F-4C75-B5F8-EE9ED5828F49Q36107216-194E49E2-7290-4691-BD91-A238E135888FQ36304307-CFBA9A5A-003B-421A-B438-8C56670EFA20Q36500869-B2D73522-14E3-4F56-AA46-940D62603949Q36586535-C7F22224-C634-491F-8BCA-0B97C694655EQ37044080-D69AEFD7-839C-4D63-B862-9016A9170333Q37115673-C57A4EB5-2BD8-49EB-B024-EE0911853FCBQ37269801-64B7616C-2BF3-4C09-A87E-5E45F41273B1Q37424157-B844574F-88A4-40EC-AFEC-0CBB5990193FQ37432620-C4AB6951-0025-49ED-ACEF-A621EE0380F8Q37505055-D4DE2B46-AD40-45EF-94A2-773D543B2E95Q37808951-CCCD77E9-7858-4355-8BF5-76E80A6865E9Q37833099-CA96B9A3-4401-40B1-AC99-DC68BEFA8184Q37855894-8F13FA32-1FF2-4B0B-A13E-F27252DDF7DDQ37997361-ED5D6EB6-AAD6-4421-AFB4-AAE86CD6127DQ38012429-E5A65723-28CF-4B63-A3EE-A0B05EE6E7ACQ38052406-F5881784-5C42-4733-BF50-008EF0CB56D5Q38105454-F0497F64-5147-4483-A998-EC2747F1612AQ38465028-A865E851-E030-4BA3-A75D-72DF9644491F
P2860
Interactions of antitumor metallodrugs with serum proteins: advances in characterization using modern analytical methodology.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Interactions of antitumor meta ...... modern analytical methodology.
@ast
Interactions of antitumor meta ...... modern analytical methodology.
@en
type
label
Interactions of antitumor meta ...... modern analytical methodology.
@ast
Interactions of antitumor meta ...... modern analytical methodology.
@en
prefLabel
Interactions of antitumor meta ...... modern analytical methodology.
@ast
Interactions of antitumor meta ...... modern analytical methodology.
@en
P50
P356
P1433
P1476
Interactions of antitumor meta ...... modern analytical methodology
@en
P2093
Andrei R Timerbaev
P304
P356
10.1021/CR040704H
P577
2006-06-01T00:00:00Z